Increased exposure & conc w/ CYP3A4 (eg, itraconazole, clarithromycin, atazanavir, idinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit juice), P-gp & BCRP inhibitors, high-/low-fat food. Decreased plasma pazopanib conc w/ CYP3A4 (eg, rifampicin) inducers. Altered exposure & distribution w/ P-gp & BCRP inducers. Altered exposure &/or distribution of CYP3A4 substrates (eg, midazolam), CYP2C8 substrates (eg, paclitaxel) & UGT1A1 substrates (eg, irinotecan & its active metabolite SN-38). Increased ratio of dextrometrophan to dextrophan conc after administration of dextrometrophan. Decreased bioavailability w/ proton-pump inhibitors (eg, esomeprazole) & other agents that increase gastric pH. Increased incidence of ALT elevations w/ simvastatin & other statins.